The GPVI collagen receptor mediates platelet activation to collagen exposed after rupture or injury of atherosclerotic plaques. Revaceptâ, a GPVI-Fc fusion protein binding to plaque collagen and concealing binding sites for platelet GPVI, acts as a lesion-focused antiplatelet drug. To optimize its specific inhibition of plaque-induced platelet activation, we cross-linked the Fc tails of GPVI-Fc with anti-human-Fc IgG or Fab2 antibodies. Cross-linking yielded oligomeric GPVI-Fc complexes, which inhibited atherosclerotic plaque-induced platelet aggregation in static and flow assays as efficiently as antibodies blocking GPVI receptors on platelets. Under arterial flow, GPVI-Fc cross-linking with anti-Fc-Fab2 was superior to cross-linking with anti-Fc IgG. Advanced optical imaging revealed a rapid and stable sheath-like coverage of collagen fibers by cross-linked GPVI-Fc complexes preventing platelet attachment to collagen. Cross-linked GPVI-Fc did not increase bleeding time in vitro. Transformation of GPVI into multivalent GPVI complexes may provide a new superior strategy to suppress atherothrombosis without increasing systemic bleeding risk.
E rosion or rupture of atherosclerotic plaques exposes material to circulating blood that triggers thrombosis and can precipitate myocardial infarction and stroke, which are leading causes of death worldwide (1, 2) . Decisive thrombogenic plaque components include collagen type I and III fibers, which trigger platelet deposition under static and flow conditions by activating the platelet glycoprotein VI (GPVI) receptor (3) (4) (5) (6) . The alternative collagen receptor, a 2 b 1 -integrin, is not involved in plaqueinduced platelet aggregation (4, 6) . Therefore, targeting GPVI might preferentially inhibit atherosclerotic plaque-induced thrombosis and should not affect other cells because GPVI expression is restricted to platelets and megakaryocytes (7) . Only the dimeric form of GPVI binds to collagen with high affinity (8, 9) , recognizing mostly tandem glycine-prolinehydroxyproline motifs but also other peptide sequences of collagen fibers (10, 11) .
The GPVI-collagen interaction can be inhibited either by occupation of GPVI-binding sites on collagen using a dimeric glycoprotein VI-fragment crystallizable (GPVI-Fc) fusion protein (Revacept; advanceCOR, Munich, Germany) or by antibodies directed against platelet GPVI (7, (12) (13) (14) (15) . Anti-GPVI antibodies might increase bleeding, as observed in some patients with anti-GPVI autoantibodies (14, 15) , whereas GPVI-Fc might be safer because it did not increase bleeding time in a Phase I study (13) . Anti-GPVI antibodies are systemic and potent inhibitors of plaque-and collagen-induced platelet aggregation under static and flow conditions, whereas GPVI-Fc acts locally at the site of plaque rupture and is in vitro most effective under high shear flow (16) .
However, GPVI-Fc inhibition of plaque-induced platelet aggregation in static assays and at low arterial shear flow is inferior to anti-GPVI antibodies (16) .
GPVI-Fc, even at very high concentrations, apparently cannot saturate all binding sites on plaque collagen. The goal of the present study, therefore, was to improve the efficacy of GPVI-Fc binding to exposed plaque collagen to combine its lesion selectivity with the full potential of GPVI antagonism as demonstrated by the anti-GPVI antibodies.
METHODS
Carotid atherosclerotic plaque tissue donated by patients undergoing endarterectomy for high-grade carotid stenosis was processed, homogenized, and preserved as described elsewhere (5, 16, 17) . Plaque homogenates from 5 patients were pooled, and aliquots were used to stimulate platelet aggregation under static conditions or were coated onto glass coverslips for flow studies (16, 18, 19) . In addition to plaque, which contains mainly type I and III collagens (4, 6) , blood was exposed to Horm collagen fibers also consisting of type I and III collagens (16) .
Nanoscopic imaging of GPVI-Fc binding and platelet adhesion to collagen under flow was performed by structured illumination microscopy (SIM) (20) 
RESULTS

GPVI-Fc, even at very high concentrations, apparently
cannot saturate all binding sites on plaque collagen and incompletely inhibits platelet aggregation (16) .
To gain further insights into the underlying mechanism, we studied the kinetics and spacial distribution at low shear flow (600/s) of how fluorescent GPVI-Fc added to blood accretes on collagen fibers and how this affects platelet adhesion, which precedes platelet aggregation. We noted that GPVI-Fc binding to collagen was very fast (Video 1), and dense GPVI-Fc dots could repel arrested platelets from stably adhering to collagen ( Figure 1A) . However, the platelets settled preferentially on segments of collagen fibers carrying little GPVI-Fc ( Figures 1A and 1B ), and they were even able to displace neighboring collagenbound GPVI-Fc to firmly attach to these collagen segments. Use of SIM confirmed that platelets stably adhered to the segments of collagen fibers, which carried little GPVI-Fc ( Figure 1C , Video 2).
We therefore aimed to modify GPVI-Fc in such a way that it would assure a more continuous binding to collagen and resist displacement by platelets. We Concentration-response curves of GPVI-Fc*Fab2-XL showed superior inhibition by GPVI-Fc*Fab2-XL at all concentrations starting with 33 nM for plaque-and collagen-stimulated samples ( Figure 2B ). These concentrations are well below the maximal plasma GPVI-Fc concentrations (50 mg/ml ¼ 333 nM) that were reached after intravenous application in a previous Phase I clinical study (13) .
We then explored the effects of GPVI-Fc antibody cross-linking on plaque-induced platelet aggregation under flow. Coronary thrombosis mostly arises from rupture of thin-capped (<65 mm) fibroatheroma, exposing the plaque lipid core containing collagenous structures to circulating blood (6, 21, 22) . This action creates a new thrombogenic and rough luminal surface that will influence platelet adhesion and aggregation dynamics probably similar to our plaque model. In our model, plaque fragments of different sizes and consisting of lipids and collagenous structures are exposed to arterially flowing blood (4, 16) . With GPVI-Fc*Fab2-XL, the inhibition was even more pronounced, and GPVI-Fc*Fab2-XL virtually abolished platelet accretion on plaque material.
Interestingly, inhibition of plaque-induced platelet aggregate formation by GPVI-Fc*IgG-XL and GPVI-Fc*Fab2-XL at the end of flow was more pronounced than after collagen stimulation.
We then compared the binding kinetics of labeled GPVI-Fc and cross-linked GPVI-Fc to collagen to explore whether a faster binding of cross-linked GPVI-Fc might explain its better inhibitory effect.
Perfusion of collagen-coated coverslips with blood PE-labeled GPVI-Fc (50 mg/ml) was added to blood containing Arg-Gly-Asp-Ser (to inhibit platelet aggregation and allow only platelet adhesion) before the start of perfusion (shear rate 550/s). After 4 min of flow, platelets were fixed and stained with anti-CD41 Ab and DyLight 488-conjugated secondary Ab (green). The fluorescence micrograph shows a maximum intensity projection of 0.15 mm z sections (total z 2.5 mm) of a structured illumination microscopy image (ELYRA PS.1; Carl Zeiss MicroImaging GmbH, Jena, Germany). i and ii, Identical pictures. i, Binding of GPVI-Fc (red) onto collagen fibers (blue). Green channel (platelets) was omitted. ii, Picture as in i but with platelets (green). Image is representative of 5 others from different experiments. Video 2 presents a 3-dimensional representation. Jamasbi et al. Figures 5A and 5B ). In the STED micrographs, in which collagen was simultaneously stained with AlexaFluor594-conjugated anti-collagen type I and III antibodies, binding of cross-linked GPVI-Fc to collagen showed complete co-localization with the anti-collagen antibodies.
Cross-linked GPVI-Fc Blocks Platelet Interaction With Plaque Collagen
To confirm our hypothesis that it is in fact cross-linking that potentiates the inhibitory effect of GPVI-Fc, inhibition of platelet aggregation on plaque and collagen fibers by GPVI-Fc*Fab2-XL were compared with that by GPVI-Fc*Fab. Fab antibodies bear only 1 antigen-binding site and are unable to cross-link antigens. Plaque-or collagen-coated surfaces were pre-incubated with either GPVI-Fc*Fab or GPVI-Fc*Fab2-XL. As expected, virtually no effect of GPVI-Fc*Fab was observed in contrast to a complete inhibition of plaque-and collagen-induced platelet 
A P R I L 2 0 1 6 : 1 3 1 -4 2 antibodies, but it is focused on the injured lesion and not burdened with systemic antiplatelet effects (unlike that of anti-GPVI antibodies). In fact, anti-GPVI antibodies may increase bleeding. Although the tail bleeding time of GPVI-deficient mice is only moderately increased (14) , a variable bleeding diathesis is observed in patients with rare genetic or acquired GPVI defects (25) .
Finally, due to the high efficacy, cross-linked GPVI-Fc can be used in much lower doses than GPVI-Fc. 
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